Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II

Histology and Histopathology

Volumn 25, Issue 3, 2010, Pages 341-349

  Ruiz, Juan ^a   Martínez, Armando ^a   Hernández, Susana ^a   Zimman, Horacio ^a   Ferrer, Milagros ^a   Fernández, Cristina ^a   Sáez, Mamen ^a   López Asenjo, Jose A ^a   Sanz Ortega, Julian ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

1p deletion; COX 2; Immunohistochemical; Meningioma; Recurrence

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

AGED; ARTICLE; CANCER INVASION; CHI SQUARE DISTRIBUTION; CHROMOSOME 1; CHROMOSOME DELETION; COHORT ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MENINGIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SEX DIFFERENCE; TISSUE MICROARRAY; TUMOR RECURRENCE;

AGED; CHI-SQUARE DISTRIBUTION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SEX FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77749287013     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Amatya V.J., Takeshima Y., Sugiyama K., Kurisu K., Nishisaka T., Fukuhara T. and Inai K. (2001). Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum. Pathol. 32, 970-975.
2. Boström J., Meyer-Puttlitz B., Wolter M., Blaschke B., Weber R.G., Lichter P., Ichimura K., Collins V.P. and Reifenberger G. (2001). Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am. J. Pathol. 159, 661-669. (Pubitemid 32751096)
3. Bruna J., Brell M., Ferrer I., Gimenez-Bonafe P. and Tortosa A. (2007). Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27, 114-120.
4. Buccoliero A.M., Castiglione F., Degl'Innocenti D.R., Arganini L., Taddei A., Ammannati F., Mennonna P. and Taddei G.L. (2007). Cyclooxigenase-2 (COX-2) overexpression in meningiomas: realtime PCR and immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 15, 187-192.
5. Burger P.C., Scheithauer B.W. and Vogel F.S. (2002). Intracranial meninges. In: Surgical pathology of the nervous system and its coverings. 4th ed. Churchill Livingstone. Elsevier Science. USA pp 49-71.
6. Choi E.M., Kwak S.J., Kim Y.M., Ha K.S., Kim J.I., Lee S.W. and Han J.A. (2005). COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp. Mol. Med. 30, 199-203.
7. Claus E.B., Park P.J., Carroll R., Chan J. and Black P.M. (2008). Specific genes expressed in association with progesterone receptors in meningioma. Cancer Res. 68, 314-322.
8. Guan Y., Hata N., Kuga D., Yoshimoto K., Mizoguchi M., Shono T., Suzuki S.O., Tahira T., Kukita Y., Higasa K., Yokohama N., Nagata S., Iñaki T., Sasaki T. and Hayashi K. (2008). Narrowing of the regions of allelic losses of chromosome 1p36 in meningioma tissues by an improved SSCP analisis. Int. J. Cancer 122, 1820-1826.
9. Kononen J., Bubendorf L., Kallioniemi A., Bärlund M., Schraml P., Leighton S., Torhorst J., Mihatsch M.J., Sauter G. and Kallioniemi O.P. (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844-847.
10. Korshunov A., Shishkina L. and Golanov A. (2002). DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. Arch. Pathol. Lab. Med. 26, 1079-1086.
11. Korshunov A., Shishkina L. and Golanov A. (2003). Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 menigiomas correlation with tumor grade and clinical outcome. Int. J. Cancer 104, 728-734.
12. Kunishio K., Morisaki K., Matsumoto Y. and Nagao S. (2000). DNA topoisomerase II alpha protein and mRNA expression in intracranial meningiomas. Brain Tumor Pathol. 17, 105-110.
13. Lewy-Trenda I., Omulecka A., Janczukowicz J. and Papierz W. (2004). CD44 expression in human meningiomas: an immunohistochemical analysis. Pol. J. Pathol. 55, 33-37.
14. Lin C.C., Kenyon L., Hyslop T., Hammond E., Andrews D.W. and Curran W.J. Jr (2003). Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. Am. J. Clin. Oncol. 26, S98-102.
15. López-Ginés C., Cerda-Nicolas M., Gil-Benso R., Callaghan R., Collado M., Roldan P. and Llombart-Bosch A. (2004). Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet. Cytogenet. 148, 123-128.
16. Louis D.N., Scheithauer B.W., Budka H., von Deimling A. and Kepes J.J. (2000). Meningiomas. In: World Health Organization classification of tumours. Pathology and genetics: tumours of central nervous system. Kleihues P. and Cavanee W. (eds). Lyon. pp 175-184.
17. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W. and Kleihues P. (2007). The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 114, 97-109.
18. Lusis E.A. and Gutmann D.H. (2004) Meningioma: an update. Curr. Opin. Neurol. 17, 687-692.
19. Maillo A., Orfao A., Espinosa A.S., Sayagues J.M., Merino M., Sousa P., Lara M. and Tabernero M.D. (2007). Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del (1p36) in the ancestral tumor cell clone. Neuro. Oncol. 9, 438-446.
20. Milenkovic S., Marinkovic T., Jovanovic M.B., Djuricic S., Berisavac I.I. and Berisavac I. (2008). Cyclin D1 Immunoreactivity in menongimas. Cell. Mol. Neurobiol. 28, 907-913.
21. Nakane Y., Natsume A., Wakabayashi T., Oi S., Ito M., Inao S., Saito K. and Yoshida J. (2007). Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. Neurosurgery 107, 398-404.
22. Panagopoulos A.T., Lancellotti C.L., Veiga J.C., de Aguiar P.H. and Colquhoum A. (2008). Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J. Neurooncol. 89, 73-87.
23. Perry A., Scheithauer B.W., Stafford S.L., Lohse C.M. and Wollan P.C. (1999). "Malignancy" in meningiomas: a clinicopathologic study of 116 patients. Cancer 85, 2046-2056.
24. Perry A., Chicoine M.R., Filiput E., Miller J.P. and Cross D.T. (2001). Clinicopathologic assessment and grading of embolized meningiomas: a correlative study of 64 patients. Cancer 92, 701-711.
25. Pfisterer W.K., Coons S.W., Abouñ-Enein F., Hendricks W.P., Scheck A.C. and Preul M.C. (2008). Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J. Neurooncol. 87, 43-50.
26. Ragel B.T. and Jensen R.L. (2003). New approaches for the treatment of refractory meningiomas. Cancer Control. 10, 148-158.
27. Ragel B.T., Jensen R.L. and Couldwell W.T. (2007). Inflamatory response and meningioma tumorigenesis and the effect of cyclooxigenase-2 inhinitors. Neurosurg. Focus 23, E7.
28. Roessler A., Gatterbauer B. and Kitz K. (2002). Topoisomerase II alpha as a reliable proliferation marker in meningiomas. Neurol. Res. 24, 241-243.
29. Sandberg D.I., Edgar M.A., Resch L., Rutka J.T., Becker L.E. and Souweidane M.M. (2001). MIB-1 staining index of pediatric meningiomas. Neurosurgery 48, 590-597.
30. Simon R., Mirlacher M. and Sauter G. (2004). Tissue microarrays. Biotechniques 36, 98-105.
31. Simpson D. (1957). The recurrence of intracranial meningiomas after surgical treatment. J. Neurol. Neurosurg. Psychiatry 20, 22-39.
32. Suzuki S.O., Iñaki T., Kitamoto T., Mizoguchi M., Fukui M. and Tateishi J. (1996). Differential expression of CD44 variants among meningioma subtypes. J. Clin. Pathol.: Mol. Pathol. 49, 140-146.
33. Terzi A., Saglam E.A., Barak A. and Soylemezoglu F. (2008). The significance of immunohistochemical expression of Ki-67, p53, p21 and p16 in meningiomas tissue arrays. Pathol. Res. Pract. 204, 305-314.
34. Vankalakunit M., Vasishta R.K., Das Radotra S. and Khosla V.K. (2007). MIB-1 immunolabelling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology 27, 407-412.
35. Whittle I.R., Smith C., Navoo P. and Collie D. (2004) Meningiomas. The Lancet 363, 1535-1544.
36. Uzüm N. and Ataoglu G.A. (2008) Histopathological parameters with ki-67 and bcl-2 in th prognosis of meningiomas according to WHO 2000 classification. Tumori 94, 389-397.